Neuropsychological and Behavioral Testing in Younger Patients With Cancer
a study on Malignant Neoplasm Neoplasms
Summary
- Eligibility
- for people ages 1 month and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study started
Description
Summary
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Official Title
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Details
PRIMARY OBJECTIVES:
- To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological/behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized time points.
OUTLINE:
Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
Keywords
Childhood Malignant Neoplasm, Neoplasms, Cognitive Assessment, Quality-of-Life Assessment
Eligibility
You can join if…
Open to people ages 1 month and up
- The patient must be currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning
- The patient must have receptive and expressive language skills in English, French, or Spanish; if a patient meets these criteria but the parent/guardian speaks a language other than English, French, or Spanish, the patient may still be enrolled and tested, and the parent-report measures should be omitted
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
You CAN'T join if...
- Patients with a history of moderate to profound intellectual disability (i.e. intelligence quotient [IQ] =< 55) are not eligible for enrollment; PLEASE NOTE: Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g., dyslexia) are eligible for this study
Locations
- Mattel Children's Hospital UCLA
Los Angeles California 90095 United States - Children's Hospital and Research Center at Oakland
Oakland California 94609-1809 United States - UCSF Medical Center-Parnassus
San Francisco California 94143 United States - UCSF Medical Center-Mission Bay
San Francisco California 94158 United States - Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance California 90502 United States - Cedars Sinai Medical Center
Los Angeles California 90048 United States - Rady Children's Hospital - San Diego
San Diego California 92123 United States - Children's Hospital Los Angeles
Los Angeles California 90027 United States - Children's Hospital of Orange County
Orange California 92868 United States - Kaiser Permanente-Oakland
Oakland California 94611 United States
Details
- Status
- in progress, not accepting new patients
- Start Date
- Sponsor
- Children's Oncology Group
- ID
- NCT00772200
- Study Type
- Observational
- Participants
- Expecting 1200 study participants
- Last Updated